Oral presentation highlighting IGNYTE main evaluation knowledge exhibits anti-tumor exercise throughout all subgroups with injected and non-injected lesions responding with related frequency, depth, length, and kinetics
Preliminary biomarker knowledge exhibits improve in tumor CD8+ T cell and PD-L1 expression after dosing together with a rise in gene signatures related to CD8+ T cells and inflammatory cytokines, highlighting the potential of RP1 plus nivolumab to generate a potent anti-tumor immune response
WOBURN, Mass., Nov. 09, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a medical stage biotechnology firm pioneering the event of novel oncolytic immunotherapies, at present introduced that the first evaluation knowledge from the IGNYTE medical trial, together with preliminary biomarker analyses, was offered as a late-breaking summary throughout an oral session on the thirty ninth Annual Assembly of the Society for Immunotherapy of Most cancers (SITC 2024) in Houston, Texas. As well as, knowledge from the ARTACUS medical trial evaluating RP1 monotherapy in stable organ transplant sufferers with superior cutaneous malignancies was additionally shared in an encore poster presentation through the assembly.
The preliminary biomarker analyses included within the SITC presentation which display will increase in tumor CD8+ T cell infiltration and PD-L1 expression together with the induction of an immune inflammatory gene signature after remedy, additional help the supposed mechanism of RP1 together with nivolumab, together with its means to induce a systemic response after development on prior anti-PD1 remedy, stated Kostas Xynos, MD, PhD, MBA, Chief Medical (TASE:) Officer of Replimune. We consider that the systemic exercise of RP1 and nivolumab is particularly demonstrated by the same degree of responses seen in each injected and non-injected lesions, together with onerous to deal with visceral lesions, and by the sturdiness of the responses seen.
IGNYTE Scientific Trial Knowledge at SITC
The IGNYTE medical trial cohort in anti-PD-1 failed melanoma included 140 sufferers who obtained RP1 plus nivolumab after confirmed development whereas being handled for at the very least 8 weeks with anti-PD-1 based mostly remedy, with or with out anti-CTLA-4. The first evaluation by blinded impartial central assessment was triggered as soon as all sufferers had been adopted for at the very least 12 months. The median follow-up on the time of the first evaluation was 15.4 months (0.5-47.6 months).
Knowledge from the IGNYTE trial offered at SITC 2024 present:
- One-third of sufferers skilled a confirmed response, with an total response charge (ORR) of 33.6% by modified RECIST (mRECIST) v1.1 standards, the first endpoint within the trial protocol, and 32.9% by RECIST v1.1 standards, a further evaluation requested by the FDA. The whole response (CR) charge by mRECIST v1.1 was 15%. In sufferers who had prior anti-PD1 and anti-CTLA-4, the ORR was 27.7% and for individuals who had main resistance to anti-PD1, the ORR was 35.9% by mRECIST v1.1.
- The median length of response from response initiation was 21.6 months.
- Most injected and non-injected lesions (85%) in responders had a 30% or larger discount in measurement. RP1 plus nivolumab induced deep responses in non-injected lesions in visceral organs, together with these distant from the injection web site.
- Median total survival for the trial has not been reached, nonetheless, one-, two-, and three-year survival charges had been 75.3%, 63.3%, and 54.8%, respectively. 12-month development free survival (PFS) was 32.8% and median PFS was 3.7 months.
Preliminary biomarker knowledge included within the SITC presentation present:
- Tumor irritation signature (TIS) and nano string evaluation revealed a rise within the expression of genes related to CD8+ T cells and inflammatory cytokines. These markers spotlight the potential of RP1 plus nivolumab to generate a potent anti-tumor immune response. TIS is an investigational use solely assay consisting of 18 genes that assesses the presence of an adaptive immune response, and which is related to responsiveness to anti-PD1 therapy1.
- Immunohistochemistry (IHC) photos display that RP1 plus nivolumab might stimulate tumors to a extra immune infected state, additional highlighting the potential of RP1 plus nivolumab to reverse mechanisms of resistance to anti-PD1 remedy.
As beforehand reported, RP1 mixed with nivolumab continues to be well-tolerated. Therapy-related antagonistic occasions related to RP1 together with nivolumab had been predominantly Grade 1-2 constitutional sort occasions (> 5% of sufferers), together with fatigue, chills, pyrexia, nausea, influenza-like sickness, injection-site ache, diarrhea, vomiting, headache, pruritis, asthenia, arthralgia, myalgia, decreased urge for food, and rash, with a low incidence (12.8% of sufferers) of Grade 3-4 occasions, which had been predominantly Grade 3. Grade 4 occasions had been one every of lipase elevated, cytokine launch syndrome, myocarditis, hepatic cytolysis, and splenic rupture. There have been no Grade 5 occasions.
The presentation is out there on the Firm web site beneath Occasions and Shows.
The IGNYTE-3 confirmatory part 3 trial evaluating RP1 plus nivolumab versus doctor’s alternative in sufferers with superior melanoma who’ve progressed on anti-PD1 and anti-CTLA-4 or who will not be candidates for anti-CTLA-4 remedy is presently recruiting. For added data, go to https://replimune.com/clinical-trials/ignyte-3/.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was based in 2015 with the mission to remodel most cancers remedy by pioneering the event of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is predicated on a potent HSV-1 spine supposed to maximise immunogenic cell dying and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a singular twin native and systemic exercise consisting of direct selective virus-mediated killing of the tumor ensuing within the launch of tumor derived antigens and altering of the tumor microenvironment to ignite a powerful and sturdy systemic response. The RPx product candidates are anticipated to be synergistic with most established and experimental most cancers remedy modalities, resulting in the flexibility to be developed alone or mixed with a wide range of different remedy choices. For extra data, please go to www.replimune.com.
Ahead Wanting Statements
This press launch comprises ahead trying statements inside the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, together with statements relating to the design and development of our medical trials, the timing and sufficiency of our medical trial outcomes to help potential approval of any of our product candidates, our objectives to develop and commercialize our product candidates, affected person enrollments in our current and deliberate medical trials and the timing thereof, and different statements recognized by phrases akin to might, expects, intends, might, plans, potential, ought to, will, would, or related expressions and the negatives of these phrases. Ahead-looking statements will not be guarantees or ensures of future efficiency and are topic to a wide range of dangers and uncertainties, lots of that are past our management, and which might trigger precise outcomes to vary materially from these contemplated in such forward-looking statements. These components embrace dangers associated to our restricted working historical past, our means to generate constructive medical trial outcomes for our product candidates, the prices and timing of working our in-house manufacturing facility, the timing and scope of regulatory approvals, the supply of mixture therapies wanted to conduct our medical trials, adjustments in legal guidelines and rules to which we’re topic, aggressive pressures, our means to determine extra product candidates, political and world macro components together with the affect of the coronavirus as a world pandemic and associated public well being points and the Russian-Ukrainian and Israel-Hamas political and navy conflicts, and different dangers as could also be detailed occasionally in our Annual Studies on Type 10-Okay and Quarterly Studies on Type 10-Q and different reviews we file with the Securities and Alternate Fee. Our precise outcomes might differ materially from the outcomes described in or implied by such forward-looking statements. Ahead-looking statements communicate solely as of the date hereof, and, besides as required by legislation, we undertake no obligation to replace or revise these forward-looking statements.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
Supply: Replimune Group Inc (NASDAQ:)
